Stent Promotes Tissue Healing

The stent has received the CE Mark.

The developer of the Genous stent, OrbusNeich (Hong Kong) has been selected as the recipient of a 2005 Technology Innovation Award from Frost & Sullivan (Palo Alto, CA, USA). Each year, this award is given to a company that has carried out new research resulting in innovations that have, or will, bring significant contributions to industry.

Genous stents promote tissue healing to occur in a rapid and controlled manner at the stent injury, rather than inhibiting healing, including endothelial coverage, with potent antiproliferative drug-eluting stents. An analysis of interim results of an ongoing clinical study called HEALING II (healthy endothelial accelerated lining inhibits neointimal growth) show that the patients who received the stent and were also on statins had better clinical outcomes. A HEALING III multifactorial clinical study will begin soon to assess the effect of statin therapy with Genous vs bare metal stents.

"Genous is not a drug-eluting stent, there is no polymer or drug,” said David Camp, vice president, sales and marketing. "The stent is coated with an antibody that captures a patient's own circulating endothelial progenitor cells. This not only minimizes restenosis but also provides immediate protection against thrombus.”

OrbusNeich supplies medical devices for vascular diseases in more than 60 countries around the world.





Related Links:
OrbusNeich